Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock?

Key Takeaways KYMR shares surged to a 52-week high amid momentum for lead candidate KT-621.KT-621 showed STAT6 degradation, biomarker reductions and a placebo-like safety profile.Parallel phase IIb studies in AD and asthma aim to speed KT-621's path toward phase 3 programs.Shares of Kymera Therapeutics, Inc. (KYMR) touched a 52-week high of $68.8 on Nov. 24. The stock is currently trading at $66.04.The rally is most likely due to investor optimism around Kymera’s lead pipeline candidate KT-621.In fact, shar ...